Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 11, 2014
 
ADMA BIOLOGICS, INC.
(Exact name of registrant as specified in its charter)
     
     
Delaware
001-36728
56-2590442
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
     
465 State Route 17 Ramsey, New Jersey
  
07446
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code: (201) 478-5552
 
 
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
Item 7.01.
Regulation FD.

Attached hereto as Exhibit 99.1 is a slide presentation that ADMA Biologics, Inc. plans to present at the Oppenheimer 25th Annual Healthcare Conference at 10:20 AM ET on December 11, 2014 at the Crowne Plaza Hotel in New York City.  A live webcast of the presentation may be accessed under the "Investor Relations" tab on the Company's website at www.admabiologics.com. A replay of the webcast will be available after the conclusion of the live event.

In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including the attached Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits

Exhibit No.
Description
   
99.1
2014 Oppenheimer 25th Annual Healthcare Conference Slide Presentation dated December 11, 2014.
 
 
 
 
 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

December 11, 2014
ADMA Biologics, Inc.
   
   
 
By:
/s/ Brian Lenz
   
Name:
Brian Lenz
   
Title:
Chief Financial Officer